AESKULISA® ASCA-A - AESKULISA ASCA-A is a solid phase enzyme - Aesku.Diagnostics GmbH & Co. KG

Duns Number:341714388

Device Description: AESKULISA ASCA-A is a solid phase enzyme immunoassay (ELISA) employing highly purified man AESKULISA ASCA-A is a solid phase enzyme immunoassay (ELISA) employing highly purified mannan for the quantitative and qualitative detection of IgA anti-Saccharomyces cerevisiae antibodies (ASCA) in human serum. ASCA recognize specifically mannan, a component of the outer cell wall of yeast. The assay is highly specific and sensitive for Crohn`s disease. 30'+30'+30' automation incubation.

Want to know more about this Product? Request more information now!


More Product Details

Catalog Number

30-7507US

Brand Name

AESKULISA® ASCA-A

Version/Model Number

30-7507US

Device Commercial Distribution Status

In Commercial Distribution

Commercial Distribution End Date

-

Issuing Agency

In GS1

Product Characteristics

MRI safety Status

Labeling does not contain MRI Safety Information

Device required to be labeled as containing natural rubber latex or dry natural rubber (21 CFR 801.437)

-

Device labeled as "Not made with natural rubber latex"

-

For Single-Use

Yes

Prescription Use (Rx)

-

Over the Counter (OTC)

-

Kit

-

Combination Product

-

Human Cell, Tissue or Cellular or Tissue-Based Product (HCT/P)

-

FDA Premarket Submission

K051492

Product Code Details

Product Code

NBT

Product Code Name

Antibodies,Saccharomyces Cerevisiae (S.Cerevisiae)

Device Record Status

Public Device Record Key

00e06e5d-5d92-46be-aefd-14bf65901303

Public Version Date

July 06, 2018

Public Version Number

3

DI Record Publish Date

February 28, 2017

Additional Identifiers

Package DI Number

None

Quantity per Package

-

Contains DI Package

-

Package Discontinue Date

-

Package Status

-

Package Type

-

"AESKU.DIAGNOSTICS GMBH & CO. KG" Characteristics
Device Class Device Class Description No of Devices
2 A medical device with a moderate to high risk that requires special controls. 77